Limitations of Nontransplant Treatment Options for Type 1 Diabetes Mellitus

  • David M. Kendall
  • Richard M. Bergenstal


For decades clinicians have recognized that elevations in blood glucose are clearly associated with an increased risk of microvascular complications of diabetes—including retinopathy, nephropathy, and neuropathy. Prior to 1993, however, no intervention trial had successfully demonstrated that intensive treatment of blood glucose could significantly reduce the risk of these complications. With the publication of the landmark Diabetes Control and Complications Trial (DCCT) in 1993,1 it was confirmed that intensive therapy could indeed reduce the risk of the secondary complications, and intensive therapy has subsequently become the standard of care for virtually all patients with type 1 diabetes.


Diabetes Control Insulin Glargine Basal Insulin Insulin Analog Intensive Therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.Google Scholar
  2. 2.
    Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973 (Parts 1 & 2). Diabetes Care 1978;1: 168–188, 252–263.Google Scholar
  3. 3.
    Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes 3. Clinical implications of UGDP results. JAMA 1971; 218: 1400–1410.PubMedCrossRefGoogle Scholar
  4. 4.
    Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetics. Lancet 1986; 2: 1300–1302.PubMedCrossRefGoogle Scholar
  5. 5.
    Olsen T, Ehlers N, Nielson CB, Beck-Neilsen H. Diabetic retinopathy after one year of improved metabolic control obtained by continuous subcutaneous insulin infusion (CSII). Acta Ophthalmol 1985; 63: 315–319.Google Scholar
  6. 6.
    Rosenstock J, Friberg T, Raskin P. Effect of glycemic control on microvascular complications in patients with type I diabetes mellitus. Am J Med 1986; 81: 1012–1018.PubMedCrossRefGoogle Scholar
  7. 7.
    Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987; 36: 808–812.PubMedCrossRefGoogle Scholar
  8. 8.
    Amthor KF, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: The Oslo Study. Diabetologia 1994; 37: 579–583.PubMedCrossRefGoogle Scholar
  9. 9.
    Diabetes Control and Complications Trial Research Group. Diabetes Control and Complications Trial (DCCT): Results of feasibility study. Diabetes Care 1992; 10: 1–19.Google Scholar
  10. 10.
    Diabetes Control and Complications Trial Research Group. Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996; 124: 379–388.Google Scholar
  11. 11.
    Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care 1996; 19: 195–203.Google Scholar
  12. 12.
    Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of longterm complications: The perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289–1298.Google Scholar
  13. 13.
    Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am 1996; 25: 243–254.PubMedCrossRefGoogle Scholar
  14. 14.
    Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304–309.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood glucose control on late complications of type 1 diabetes. Lancet 1993; 341: 1306–1309.PubMedCrossRefGoogle Scholar
  16. 16.
    Strowig S, Raskin P. Glycemic control and diabetic complications. Diabetes Care 1992; 15: 1126–1140.PubMedCrossRefGoogle Scholar
  17. 17.
    Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381–389.Google Scholar
  18. 18.
    Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996; 276: 1409–1415.Google Scholar
  19. 19.
    Hirsch lB, Farkas-Hirsch R, Skyler JS. Intensive insulin therapy for treatment of type I diabetes. Diabetes Care 1990; 13: 1265–1283.PubMedCrossRefGoogle Scholar
  20. 20.
    Holleman F, van den Brand JJ, Hoven RA, et al. Comparison of LysB28, ProB29 human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 1996; 19: 1426–1429.PubMedCrossRefGoogle Scholar
  21. 21.
    Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 1999; 22: 1607–1611.PubMedCrossRefGoogle Scholar
  22. 22.
    Brunelle BL, Llewelyn J, Anderson JH Jr, Glae EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21: 1726–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583–588.PubMedCrossRefGoogle Scholar
  24. 24.
    Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group (in-process citation). Diabetes Care 2000; 23: 1137.PubMedCrossRefGoogle Scholar
  25. 25.
    Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK. The impact of the Diabetes Control and Complications Trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001; 24: 430–434.PubMedCrossRefGoogle Scholar
  26. 26.
    Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779–1784.PubMedCrossRefGoogle Scholar
  27. 27.
    Zinman B, Tildesley H, Chiasson J-L, et al. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 1997; 46:440–143.Google Scholar
  28. 28.
    Bergenstal R, Callahan T, Johnson M, Upham P, Hollander P, Spencer M, Castle G, Nelson J, Roth L, Etzwiler D. Management principles that most influence glycemic control: A follow-up study of former DCCT participants. Diabetes 1996; 45 (suppl 12): A456.Google Scholar
  29. 29.
    McCulloch DK, Mitchell RD, Ambler J, Tattersall RB. Influence of imaginative teaching of diet on compliance and metabolic control in insulin dependent diabetes. Br Med J 1983; 287: 1858.CrossRefGoogle Scholar
  30. 30.
    Rabasa-Lhoret R, Garon J, Langlier H, et al. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralenteregular) insulin regimen. Diabetes Care 1999; 22: 667–673.PubMedCrossRefGoogle Scholar
  31. 31.
    Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of noninsulin-dependent diabetes mellitus: A randomized, controlled clinical trial. J Am Diet Assoc 1995; 95: 1009–1017.PubMedCrossRefGoogle Scholar
  32. 32.
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2001; 24 (suppl 1): S33 - S43.Google Scholar
  33. 33.
    Diabetes Control and Complications Trial Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991; 90: 450–459.Google Scholar
  34. 34.
    Bolli GB. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Diabetes Care 1999; 22 (suppl 2): B43 - B52.PubMedGoogle Scholar
  35. 35.
    Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271–286.Google Scholar
  36. 36.
    Egger M, Davey Smith G, Stettler C, et al. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: A meta-analysis. Diabetes Med 1997; 14: 919–922.CrossRefGoogle Scholar
  37. 37.
    Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994; 43: 1378–1389.PubMedCrossRefGoogle Scholar
  38. 38.
    Kendall DM, Rooney DP, Smets YFC, Bolding LS, Robertson RP. Pancreas transplantation restores epinephrine secretion and symptom awareness during hypoglycemia in patients with longstanding type I diabetes and autonomic neuropathy. Diabetes 1997; 46: 249–257.PubMedCrossRefGoogle Scholar
  39. 39.
    Kendall DM, Teuscher AU, Robertson RP. Defective glucagon secretion during hypoglycemia following intrahepatic islet alloand autotransplantation in humans. Diabetes 1997; 46: 23–27.PubMedCrossRefGoogle Scholar
  40. 40.
    Gupta V, Wahoff DC, Rooney DP, Poitout V, Sutherland DER, Kendall DM, Robertson RP. Defective glucagon responses from transplanted intrahepatic islets during hypoglycemia are transplantation site determined. Diabetes 1997; 46: 28–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Diabetes Control and Complications Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complication Trial. Diabetes Care 1988; 11: 567–573.Google Scholar
  42. 42.
    Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. Results from the DCCT. JAMA 1998; 280: 140–146.PubMedCrossRefGoogle Scholar
  43. 43.
    American Diabetes Association. Clinical Practice Recommendations 2001. Pancreas transplantation for patients with type 1 diabetes. Diabetes Care 2001; 24 (suppl 1): S93.Google Scholar
  44. 44.
    Federlin K, Pozza G. Indications for clinical islet transplantation today and in the forseeable future-the diabetologist’s point of view. J Mol Med 1999; 77: 148–152.PubMedCrossRefGoogle Scholar
  45. 45.
    Diabetes Control and Complications Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 1468–1478.Google Scholar
  46. 46.
    Gruessner AC, Sutherland DER. Report for the international pancreas transplant registry-2000. Transplant Proc 2001; 33: 1643–1646.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • David M. Kendall
  • Richard M. Bergenstal

There are no affiliations available

Personalised recommendations